Imatinib is a member of the class of …References (0) Cited by (2) Fabrication, characterization and performance evaluation of an amplified electrochemical sensor based on MOFs nanocomposite for leukemia drug Imatinib determination 2023, Sensing and Bio-Sensing Research Citation Excerpt : The main pro...
2001年,第一种激酶抑制剂伊马替尼(imatinib)获得批准,用于治疗慢性髓系白血病。在此之后,该领域又了重大进展,随后70多种激酶抑制剂获得批准。 Nature Reviews Drug Discovery的这张海报展示了过去20年来在开发激酶抑制剂方面取得的关键进展,包括:对人类激酶分子和结构的深入理解,治疗中对抗耐药性的策略的出现,了解到联...
Imatinib is the first tyrosine kinase inhibitor (TKI) approved for human therapy, and it is a milestone for the development of the entire class of kinase inhibitors; its history of drug development, approval, efficacy, and safety has become paradigmatic in the whole field of targeted medicines....
目前，Imatinib已在美国、巴西、瑞士及澳大利亚等35个国家上市。在美国，Imatinib由于疗效确切，只用了32个月就获得上市批准，而普通药物通常需要近6年的时间。目前正在进行的是将Imatinib用于其它肿瘤治疗的试验，预计这个“重磅炸弹”在2005年的年销售额将突破10亿美元。Imatinib is a drug used to treat ...
A brief account of similar cases of TKI drug-induced immune thrombocytopenia (DIT) is also described. 展开 关键词: Drug-induced immune thrombocytopenia Imatinib Myelosuppression Thrombocytopenia Tyrosine kinase inhibitor DOI: 10.1016/j.jtumed.2015.01.005 被引量: 3 ...
Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML). Preclinical studies were promising but the results of clinical trials by far ex... Deininger,M. - 《Blood》 被引量: 2020发表: 2005年 The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "...
Gleevec is not the only drug of its kind: It was the first in a class of medications known as tyrosine kinase inhibitors, or TKIs. Since 2001, so-called “second-generation” TKIs -- including the drugs dasatinib (Sprycel) and nilotinib (Tasigna) -- have been approved for chronic myel...
In addition, there may beincreased levels of the kinase itself. The drug is also a substratefor Pgp and an additional efflux transporter known asbreast cancer resistance protein (BCRP), both of which removethe drug from the cell. These transporters are also inhibitedby the agent as well. ...
In addition, Novartis has announced that the application of imatinib in treating hypereosinophilic syndrome and systemic mastocytosis is still in the approval process of FDA and EMEA. The drug has currently been approved in Europe, the United States and other countries for the treatment of Philade...
It is also suggest that imatinib mesylate is the potential drug for clinical usage as AID suppressor, which deregulation of CSR and SHM with the genomic instability is observed in many B cell malignancy. Disclosures No relevant conflicts of interest to declare. 展开 ...